Anbang Pharmaceutical

Anbang Pharmaceutical upholds the corporate mission of "Great Love of Heaven and Earth, Health for All with Anbang", serving the country through industry and building the enterprise with great love, persisting in high-quality innovative development. Anbang Pharmaceutical is a modern traditional Chinese medicine (TCM) enterprise that closely follows national strategies, leverages the advantages of traditional Chinese medicine, and conducts original innovation targeting major diseases, high-incidence diseases, and emerging diseases. At present and for a considerable period to come, some diseases that seriously threaten human health remain incurable, providing enormous space for the development of TCM modernization. Tu Youyou's Nobel Prize has made the global scientific community realize the immense potential of traditional Chinese medicine, just as Qian Xuesen predicted: "The modernization of traditional Chinese medicine may trigger a revolution in medicine, and a revolution in medicine may trigger a revolution in the entire science." Starting from research on innovative TCM theories and secret prescriptions from TCM families, Anbang Pharmaceutical has carried out modern clinical research and innovative modern pharmaceutical technology. It has already achieved breakthroughs in chronic obstructive pulmonary disease (COPD) and intrauterine adhesions, forming a series of innovative TCM drugs covering both the acute exacerbation and remission phases of COPD. The Class 1.1 innovative TCM drug Qijiao Tiaojing Granules has been successfully approved and included in the national medical insurance through national negotiations. The company has established a workstation for academicians and a provincial-level engineering technology center to conduct in-depth and systematic scientific research and innovation in fields such as post-pulmonary infection sequelae, pulmonary nodules, and menopausal mental disorders. The company has taken the lead in the internationalization of traditional Chinese medicine, having completed registration of some products in countries such as Pakistan, Zimbabwe, and Poland. In terms of market strategy, Anbang Pharmaceutical actively lays out a grassroots chronic disease management system that "synergizes with hierarchical diagnosis and treatment." "Serious and acute diseases are treated at higher-level hospitals, while minor and chronic diseases are managed at grassroots levels" is an inevitable trend for the development of a high-quality medical system and a global healthcare trend. Combining its product and R&D advantages, Anbang Pharmaceutical insists on research and practice in grassroots chronic disease diagnosis and treatment services, collaborating with grassroots medical institutions to establish a patient-centered, full-course, all-round, online-offline coordinated chronic disease management system. Currently, the company has gained a first-mover advantage in the field of grassroots respiratory chronic disease management and is actively expanding into common grassroots chronic disease markets such as cardiovascular and cerebrovascular diseases, gynecology, and rheumatic bone pain, striving to become China's leading enterprise in grassroots chronic disease management. Anbang Pharmaceutical establishes the enterprise with great love and actively undertakes social responsibilities. It is one of the larger welfare enterprises in the pharmaceutical industry and is designated as a "National Base for Proportional Employment of Persons with Disabilities." The company's chairman, Chen Feibao, has been recognized as an "Outstanding Private Entrepreneur Caring for Employees Nationwide."